In this Issue:
CD49d for predicting OS in CLL
Eltrombopag restores trilineage haematopoiesis in refractory aplastic anaemia
Endpoints for clinical trials in elderly haematological malignancies
Pharmacokinetics and safety of SC rituximab in FL
Second primary malignancies with lenalidomide for MM
Bendamustine+ofatumumab in relapsed/refractory CLL
Idelalisib+rituximab in relapsed CLL
Idelalisib in relapsed indolent lymphoma
Paediatric IV pegaspargase regimen adapted for adults with ALL
Please login below to download this issue (PDF)